Back to Journals » ImmunoTargets and Therapy » Volume 2

The association between Lambert–Eaton myasthenic syndrome and small cell lung carcinoma

Authors Briggs S, Gozzard P, Talbot DC

Received 9 February 2013

Accepted for publication 27 March 2013

Published 22 May 2013 Volume 2013:2 Pages 31—37


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Sarah EW Briggs,1 Paul Gozzard,2 Denis C Talbot3

1Department of Oncology, Oxford University Hospitals Trust, Churchill Hospital, Oxford, UK; 2Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford UK; 3Department of Oncology, Oxford University Hospitals Trust, Churchill Hospital, Oxford, UK

Abstract: Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disorder mediated by autoantibodies to voltage-gated calcium channels. The disorder is diagnosed clinically on the basis of a triad of symptoms (proximal muscle weakness, hyporeflexia, and autonomic disturbance), supported by electrophysiological findings and the presence of autoantibodies. Between 40% and 62% of patients diagnosed with LEMS are found to have small-cell lung cancer (SCLC), almost all of whom develop neurological symptoms before their cancer is diagnosed. Prompt identification of LEMS and appropriate screening for SCLC is key to improving the outcome of both conditions. Here we review the pathophysiology and clinical management of LEMS, focusing particularly on the relationship with SCLC.

Keywords: Lambert–Eaton, small-cell lung cancer, autoimmune

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]